Alembic Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Alembic Pharmaceuticals announced that the 15th Annual General Meeting(AGM) of the company will be held on 5 August 2025.

Powered by Capital Market - Live News

Alembic Pharmaceuticals has fixed 29 July 2025 as record date for determining the entitlement of members of the Company to receive dividend for the financial year ended 31 March 2025. The payment of dividend will be made on or from Thursday, 7 August 2025, upon the same being approved at the Annual General Meeting scheduled to be held on 5 August 2025.

Powered by Capital Market - Live News

According to a regulatory filing, the USFDA conducted an unannounced and routine current good manufacturing practices (cGMP) inspection at the company?s API-I and API-II facilities located at Panelav from 26 May 2025 to 31 May 2025.

The USFDA issued a form 483 with four observations and none of the observations are related to data integrity and management believes that they are addressable.

The company will provide comprehensive response to USFDA for the observations within the stipulated period.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.

The company?s consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.

Powered by Capital Market - Live News

Bosutinib tablets are indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who have shown resistance or intolerance to prior therapy.

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Bosulif Tablets, marketed by PF Prism C.V. (Pfizer).

According to IQVIA, Bosutinib Tablets have an estimated market size of $ 291 million for the twelve months ending March 2025.

Alembic has a cumulative total of 223 ANDA approvals (200 final approvals and 23 tentative approvals) from USFDA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.

The company?s consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.

The counter rose 0.97% to Rs 1,015.30 on the BSE.

Powered by Capital Market - Live News